


Study Group – Sarcoma

Our project is investigating the value of local ablative therapy (LAT) in oligometastatic soft tissue sarcoma (STS). We aim to identify patient groups that benefit the most from LAT.

Speaker: Prof. Lars Lindner, Munich (LMU); PD Matthias Grube, Regensburg

Concept & Achievements

1. Timeline



2. Background

- Oligometastatic soft tissue sarcoma (STS): Intermediate stage between localized and widespread metastatic disease
- Until now, decisions on local ablative treatment (LAT) of oligometastasis in patients with STS are made based on an individual and situational case discussion in the tumor board
- Therefore, evidence-based treatment recommendations for LAT are urgently needed

3. Methods

- Retrospective exploratory analysis of **n=234** oligometastatic STS patients from all BZKF sites with recommendation of LAT in the local sarcoma tumor board from 2017- 2021
- Detailed information about all local and systemic therapies are reported on a common biomedical platform CentraXX

4. Preliminary Results

- Median overall survival: 5.4 years, 2-year survival: 82.9% (all patients from first metastasis)
- Prognostic factors for OS/PFS in univariate analysis: Histology of leiomyosarcoma, >2 LAT in the course of disease, time interval from first diagnosis to first metastasis ≥ 12 months, single treated metastatic lesion
- Remaining questions to be answered soon: Which sarcoma types have the greatest benefit from which LAT? Which therapy sequence is ideal? Should systemic therapy always be performed?




Figure 1: Local ablative therapies (LAT) and metastatic sites




Figure 2: Overall survival from diagnosis of first metastasis according to most common STS subtypes




Figure 3: Progression-free survival after first local ablative therapy (LAT) according to number of treated lesions

Future Milestones

- » Final evaluation of existing retrospective data, submission of a first manuscript and presentation of results at CTOS in November 2023
- » Subgroup and discipline-specific analyses of existing data
- » Implementation of a prospective study of all patients with metastatic soft tissue sarcoma (not only oligometastatic)
- » Translational projects in the context of the prospective study

Authors: Anton Burkhard-Meier (LMU), Matthias Grube (UKR), Markus Albertsmeier (LMU), Vindi Jurinovic (LMU), Carolin Knebel (TUM), Ulrich Lenze (TUM), Norbert Meidenbauer (UKE), Sabine Semrau (UKE), Martin Trepel (UKA), Armin Wiegering (UKW), Lars H. Lindner (LMU)

